Report Highlights

Industry Snapshot

The UK Glucagen Injection market was valued at approximately USD 48.6 million in 2024 and is projected to reach approximately USD 112.4 million by 2034, growing at a CAGR of 8.7%–10.2% over the forecast period. This is a small but structurally significant market operating at the intersection of diabetes care innovation, NHS formulary policy, and post-Brexit pharmaceutical regulatory evolution. The UK accounts for approximately 8%–10% of the European glucagon rescue therapy market and is positioned as the most commercially dynamic major European glucagon market due to the MHRA's increasing willingness to evaluate novel formulations on their own merits independent of EMA decisions, and the NHS England's structured technology evaluation through NICE guidance. Total insulin-dependent diabetes prevalence in the UK is approximately 400,000 (Type 1) plus approximately 800,000 insulin-treated Type 2 patients — the eligible glucagon rescue therapy population is the entire insulin-dependent cohort, of whom an estimated 35%–45% have active glucagon rescue prescriptions.

The competitive structure has been reshaped by the 2021–2023 approval and NHS formulary inclusion of next-generation glucagon rescue products. Eli Lilly's Baqsimi (nasal glucagon powder) received NICE Technology Appraisal positive guidance in 2022, establishing reimbursement and opening competition with Novo Nordisk's long-dominant GlucaGen kit. Zealand Pharma's Zegalogue (dasiglucagon ready-to-inject) and Xeris Pharmaceuticals' Gvoke (liquid stable glucagon) have both received MHRA approval but have not yet achieved broad NHS formulary positioning, creating a dynamic where approval does not automatically translate to reimbursed market access — a structural feature of the NHS market all entrants must navigate.

Competitive Intensity Assessment

UK glucagon injection market competition is moderate in the conventional product tier and intensifying in the next-generation product tier, with the most significant competitive tension occurring at the NHS formulary positioning stage rather than at the clinical performance stage. On active competitor count: four approved glucagon products compete for UK NHS prescriptions — GlucaGen (Novo Nordisk), Baqsimi (Lilly), Zegalogue (Zealand Pharma), and Gvoke (Xeris). On price competition: NICE Technology Appraisals effectively set competitive pricing frameworks, with the GBP 20,000–30,000 per QALY cost-effectiveness threshold defining the price ceiling for positive guidance; Baqsimi's successful NICE appraisal at a price premium over GlucaGen established the precedent that convenience formulation improvements justify premium pricing in this indication. On product differentiation: differentiation is genuinely meaningful in glucagon — the difference between a conventional lyophilised kit requiring 6 manual steps and a nasal powder requiring a single nostril administration affects real-world rescue success rates, particularly when the hypoglycaemia episode is severe enough to impair patient dexterity. On switching costs: low at the individual patient level but high at the Integrated Care Board commissioning level, where formulary decisions affect thousands of patients simultaneously and are reviewed only annually. On barriers to entry: MHRA approval requires Phase 3 hypoglycaemia rescue data, manufacturing site GMP certification, and NHS commercialisation infrastructure — a combined investment of GBP 15–30 million that limits credible new entrants to established pharmaceutical companies.

The two companies whose competitive actions will most significantly reshape UK glucagon market share through 2028 are Novo Nordisk and Xeris Pharmaceuticals. Novo Nordisk faces the structural challenge of defending GlucaGen incumbency against next-generation formulations that are objectively superior in ease of use, despite GlucaGen's established NHS formulary positioning and prescriber familiarity advantage. Xeris Pharmaceuticals' Gvoke has the clinical advantage of liquid stability at room temperature for 24 months versus GlucaGen's requirement for immediate use after reconstitution, but has not yet achieved broad NHS formulary inclusion due to slower NICE submission and incomplete ICB commissioning engagement. Xeris' UK headquarters provides regulatory affairs agility — faster MHRA engagement on licence variation submissions — that partially compensates for its smaller commercial scale.

Market Growth Drivers

The primary structural growth driver is the NHS England's Type 1 diabetes technology program — specifically the expansion of closed-loop insulin delivery systems to a broader patient population. NICE's 2023 Technology Appraisal guidance TA943 recommended expansion to all Type 1 diabetes patients who do not achieve HbA1c targets on conventional insulin pump therapy. Critically for glucagon market dynamics, closed-loop system protocols uniformly recommend that glucagon rescue therapy is prescribed and immediately accessible to closed-loop users as a safety backstop, creating a committed glucagon prescription for each closed-loop system adoption. With NHS England targeting 70,000 closed-loop system users by 2025, each new system adoption represents a glucagon rescue therapy prescription — a committed demand increment independent of natural disease prevalence trends.

The MHRA's post-Brexit regulatory independence is increasingly relevant as a supply-side driver. Since the UK's full separation from EMA procedures in 2021, the MHRA has demonstrated willingness to grant UK approvals ahead of EMA decisions in several therapeutic areas. The MHRA's 2024 consultation on simplified approval pathways for insulin and glucagon product improvements under the existing licence variation framework creates a potential 6–12 month first-to-UK approval advantage for products that route through MHRA before EMA submission — an opportunity that Xeris Pharmaceuticals and Zealand Pharma are both pursuing for their next-generation device variants.

Market Restraints and Challenges

The structural constraint most specific to the UK glucagon market is the NHS England Integrated Care Board commissioning fragmentation created by the 2022 NHS restructuring. Glucagon products that achieve NICE Technology Appraisal approval are mandatorily funded, but products recommended in NICE guidelines (non-mandatory guidance) are subject to individual ICB formulary decisions — a fragmentation that creates 42 separate NHS commissioning conversations for products seeking guideline rather than appraisal status. Zealand Pharma's Zegalogue is affected by this: its MHRA approval is established but its primary route to NHS formulary access through NICE guidelines rather than a mandatory Technology Appraisal creates patchy reimbursement availability across ICBs despite clinical advantages in paediatric use.

The competitive challenge most constraining next-generation glucagon product adoption is prescriber and patient inertia around GlucaGen. Despite the clinical superiority of nasal and liquid-stable glucagon in real-world use scenarios, UK endocrinologists and diabetes specialist nurses have established prescribing routines around GlucaGen supported by decades of prescriber education investment from Novo Nordisk. NHS prescribing data shows that GlucaGen retains approximately 55%–60% of UK glucagon volume despite available approved alternatives, reflecting institutional inertia that new entrants must overcome through clinical educator engagement, patient advocacy support, and primary care repeat prescription system updates — a behaviour change campaign requiring 2–3 years of sustained commercial investment.

Emerging Opportunities

The most UK-specific near-term opportunity is the NICE guideline update for diabetes technology expected in 2025–2026, anticipated to include specific guidance on glucagon rescue formulation selection addressing patient subgroups (paediatric, elderly with dexterity impairment, severe hypoglycaemia unawareness) where next-generation formulations have documented clinical advantages. A positive NICE guideline statement specifically recommending nasal or ready-to-inject glucagon for defined patient subgroups would accelerate ICB formulary inclusion and shift NHS prescribing patterns faster than current organic adoption. Eli Lilly's Baqsimi NICE submission was structured to support exactly this pathway, and the anticipated guideline update is expected to reference Baqsimi's superior successful rescue rates in paediatric real-world studies conducted in UK diabetes centres.

The second UK-specific opportunity is glucagon market expansion through hypoglycaemia unawareness treatment protocols. Impaired awareness of hypoglycaemia (IAH) affects approximately 25% of UK Type 1 diabetes patients and is associated with significantly increased severe hypoglycaemia frequency. The NHS Clinical Reference Group for Diabetes has been developing structured hypoglycaemia management pathways that include glucagon rescue prescribing as a standard element of IAH management — a clinical pathway formalisation that would expand glucagon rescue prescriptions beyond the current rate by systematically including the IAH patient population. The addressable market increment from IAH-specific prescribing protocols is estimated at GBP 4–8 million annually.

Regulatory and Policy Landscape

The UK glucagon injection market is regulated by the MHRA under the Human Medicines Regulations 2012. Post-Brexit, the MHRA has introduced the International Recognition Procedure allowing approved medicines from FDA, EMA, Health Canada, and TGA to receive expedited UK approval — a framework that Eli Lilly successfully used for Baqsimi's UK authorisation on the basis of its FDA approval, reducing the review timeline by approximately 9 months versus a standard national procedure. NHS England's technology assessment process through NICE Technology Appraisals (for statutory funding mandates) and NICE guidelines (for non-mandatory recommendations) is the primary commercial access mechanism; NICE's cost-effectiveness threshold of GBP 20,000–30,000 per QALY has consistently accommodated premium pricing for products demonstrating meaningful clinical improvement over standard of care.

Leading Market Participants

• Novo Nordisk UK (GlucaGen, HypoKit)
• Eli Lilly UK (Baqsimi nasal glucagon)
• Zealand Pharma (Zegalogue, through distribution partner)
• Xeris Pharmaceuticals (UK-headquartered, Gvoke)
• Amphastar Pharmaceuticals (through UK distributor)
• Fresenius Kabi (hospital glucagon injection supply)
• Pfizer UK (hospital glucagon injection supply)
• Alliance Pharma (UK market access partner)

Domestic vs. International Dynamics

International pharmaceutical companies — Novo Nordisk, Eli Lilly, Zealand Pharma, Amphastar — control approximately 88%–92% of UK glucagon rescue therapy revenue, reflecting the capital intensity of pharmaceutical development and manufacturing that prevents a UK-domestic glucagon manufacturer from existing at commercial scale. Xeris Pharmaceuticals represents the sole UK-headquartered participant in the branded glucagon market, and while its Gvoke product has MHRA approval, its NHS market penetration remains limited by commissioning fragmentation and smaller sales force relative to Novo Nordisk and Lilly. International manufacturers' structural advantages are manufacturing scale, clinical trial infrastructure, and established NHS commercial infrastructure including NICE submission experience and ICB formulary management capabilities.

The balance is shifting marginally toward domestic participation in the context of post-Brexit NHS procurement policy. The NHS Commercial Framework and the DHSC's Life Sciences Vision 2031 both include explicit commitments to support UK life science manufacturing and commercial activity as procurement selection criteria — creating a systematic (if modest) preferential environment for UK-headquartered pharmaceutical companies in NHS procurement negotiations. For Xeris Pharmaceuticals specifically, this policy tailwind could accelerate ICB formulary inclusion if it actively positions its UK-headquartered status as a procurement selection factor alongside clinical evidence in commissioning committee submissions.

Long-Term Market Perspective

The UK glucagen injection market will grow steadily through 2034 as Type 1 diabetes technology adoption expands glucagon co-prescribing, NICE guideline updates clarify product selection for specific patient subgroups, and the IAH prescribing protocol formalisation expands the treated population. Novo Nordisk will remain the volume market leader through GlucaGen's institutional inertia but will progressively cede value share to Baqsimi and next-generation device formulations as NICE guidance updates reflect clinical evidence for formulation-specific benefits in paediatric and elderly patients. By 2034, the market will be characterised by three or four co-existing approved products serving defined patient subgroup niches, rather than the winner-takes-all displacement dynamic that characterises some pharmaceutical market segments.

Investment in UK glucagon market positioning through 2034 should prioritise NHS commissioning infrastructure — specifically ICB formulary engagement programs and NICE guideline submission support — over clinical trial investment, since the primary access barrier is commercial not scientific. The scenario most likely to significantly accelerate market growth beyond the base case is a NICE mandatory Technology Appraisal for next-generation glucagon products across all insulin-dependent diabetes patients — a policy decision that would mandate NHS funding at the ICB level and remove the commissioning fragmentation that limits next-generation product adoption to approximately 40%–50% of ICBs.